In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X Institute Launches Ukraine Refugee Funding Program
BioMed X Institute Launches Ukraine Refugee Funding Program
Lab Manager
The program addresses early-career scientists (either master-level scientists or doctoral students) in the field of life sciences who cannot continue their research at their Ukrainian institutions.
Visit: Artificial Intelligence âBoot Campâ Aims to Accelerate Drug Discovery
Artificial Intelligence âBoot Campâ Aims to Accelerate Drug Discovery
Health Policy Watch
Together with its German partner BioMed X, AION Labs hosted 15 teams of computational biologists, AI researchers and biomedical scientists for a âboot campâ that aims to speed up the drug discovery process and lower costs â harnessing AI technologies in novel ways.
Visit: Joint Research Project to Examine Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging
Joint Research Project to Examine Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging
LABMATE Online
A German independent research institute, BioMed X, announces today the start of its new research project âRegulatory T Cell Dysfunction in Autoimmunity and Inflammagingâ (TDA) in collaboration with Merck KGaA, Darmstadt, Germany.
Visit: BioMed X Institute and Merck KGaA Start Second Research Project in Immunology
BioMed X Institute and Merck KGaA Start Second Research Project in Immunology
PharmTech
BioMed X and Merck KGaA, Darmstadt, Germany announced their collaboration on a research project to study T-cells and autoimmunity.
Visit: BioMed X Initiates New Research Project in Collaboration with Merck
BioMed X Initiates New Research Project in Collaboration with Merck
Contract Pharma
Research team will examine âRegulatory T Cell Dysfunction in Autoimmunity and Inflammaging.â
Visit: BioMed X Institute and Boehringer Ingelheim Start New Research Project in Brain Sensor Development
BioMed X Institute and Boehringer Ingelheim Start New Research Project in Brain Sensor Development
PharmiWeb
Research team âBDBâ to develop an advanced biosensor for pharmacological monitoring in the brain. Fifth joint reseach project of the partners since 2014
Visit: Brain Training: BioMed X Institute collaborates with Boehringer Ingelheim
Brain Training: BioMed X Institute collaborates with Boehringer Ingelheim
PharmaTimes
Sensor development project marks the fifth joint research effort between BioMed X with Boehringer Ingelheim
Visit: AION Labs: At the forefront of the pharmaceutical revolution
AION Labs: At the forefront of the pharmaceutical revolution
The Jerusalem Post
Four times a year, five teams of scientists are invited to Israel for a five-day intensive boot camp, during which they solve a challenge relevant to todayâs pharma industry.
Visit: Israel’s AION Labs Lanches Third Call For Proposals To Develop Antibody Therapies
Israel’s AION Labs Lanches Third Call For Proposals To Develop Antibody Therapies
nocamels
Israeli-headquartered, AION Labs, and German independent research institute, BioMed X, this week announced their third global call for biomedical scientists and interested investors to apply for a new AION Labs startup in Rehovot focused on âAI-enabled design and optimization of antibodies for targeted therapiesâ.
Visit: AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
AITHORITY
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of the third global call for application to identify biomedical scientists and inventors to form a new startup at AION Labsâ headquarters in Rehovot, Israel.
Visit: BioMed X institute and Merck KGaA extend cancer collaboration
BioMed X institute and Merck KGaA extend cancer collaboration
thepharmaletter
German independent research institute BioMed X says it has extended its collaboration with Merck KGaA, Darmstadt, Germany.
Visit: Unravelling New Disease Biology at the Interface Between Academia and the Pharma Industry
Unravelling New Disease Biology at the Interface Between Academia and the Pharma Industry
European Biopharmaceutical Review
Making the case for focusing investments on drug discovery over development. What are some of the innovation models that have thrived, and what are the key success factors in those models?
Visit: Ein Pionier der translationalen biomedizinischen Forschung â Das BioMed X Institut in Heidelberg
Ein Pionier der translationalen biomedizinischen Forschung â Das BioMed X Institut in Heidelberg
BioDeutschland Jahrbuch 2021/2022
Meilensteine in der Medizin sind meist das Ergebnis von in- novativer, kreativer und risikoreicher Forschung. Eines der fĂŒh- renden Zentren in Deutschland an der Schnittstelle zwischen akademischer und industrieller biomedizinischer Forschung ist das BioMed X Institut in Heidelberg.
Visit: Big pharma finds Israel’s drug development role
Big pharma finds Israel’s drug development role
Globes
AION Labs will set Israeli computing talent to solving international pharma companies’ problems. CEO Mati Gill and adviser Christian Tidona explain.
Visit: Merck, BioMedX Institute collaboratively complete 4th project in Oncology
Merck, BioMedX Institute collaboratively complete 4th project in Oncology
Medical Dialogues
German independent research institute BioMed X has recently announced the successful completion of the research project DNA Damage in Cancer (DDC) in collaboration with Merck KGaA, Darmstadt, Germany.
Visit: Seeding Biomedical Innovations
Seeding Biomedical Innovations
Business Focus Magazine
BioMed X is an independant research institue located within the campus environment of the university of Heidelberg in Germany.
Visit: AION Labs’ Challenge To AI Drug Development Innovators
AION Labs’ Challenge To AI Drug Development Innovators
BioProcess Online
Mati Gillâs exposure to the power of pharma collaboration canât be overstated. During his 11 years as COO of the Global Legal Group, and later, head of government affairs, corporate & international markets at Teva Pharmaceuticals, he was exposed to virtually every aspect of the business.
Visit: Call for application: AI for antibody design
Call for application: AI for antibody design
Drug Discovery World
German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup atâŻAIONâŻLabsâ, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges.
Visit: An Israeli Lab Tests A Unique Way Of Collaborating and Scaling AI
An Israeli Lab Tests A Unique Way Of Collaborating and Scaling AI
The Innovator News
A new lab formed by four pharmaceutical companies, a German biomedical research institute, a venture capital firm, and Amazon Web Services is creating a radically different model for drug discovery that could become a blueprint for how companies collaborate, scale AI and work with startups in future.
Visit: Pfizer, Merck, and AstraZeneca back Israeli innovation hub for AI in drug discovery
Pfizer, Merck, and AstraZeneca back Israeli innovation hub for AI in drug discovery
AI Business
AWS has joined pharma giants AstraZeneca, Pfizer, Merck, and Teva to launch AION Labs â an innovation hub designed to develop AI for use in drug discovery.
Visit: AION Labs spots ‘unique opportunity’ for AI-driven antibody discovery
AION Labs spots ‘unique opportunity’ for AI-driven antibody discovery
Biopharma Reporter
AION Labs, a new innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, has announced a global call for application to identify biomedical scientists and inventors to form a new startup at its headquarters in Rehovot, Israel.